NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

The data was presented today in a poster session at the American Academy of Neurology (AAN) 2025 Annual Meeting in San Diego. “The favorable tolerability and pharmacokinetic profile observed with ...